STOCK TITAN
  1. Home
  2. Sec-filings
  3. LENZ
  4. [Form 4] LENZ Therapeutics, Inc. Insider Trading Activity

Form 4: Versant entities dispose 188,094 LENZ shares across Aug 22–26, 2025

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Versant entities reported multiple sales of LENZ Therapeutics common stock on August 22, 25 and 26, 2025. The filing lists a series of non-derivative sales totaling 188,094 shares across those dates at weighted-average prices in ranges between $38.50 and $40.8819 per share. The reporting parties include Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P. and Versant Vantage II, L.P., and related general partner and GP-GP entities. Footnotes state that certain holdings are held indirectly by VVC VI, VVC VII and VV II, and that the reporting entities may be deemed to share voting, investment and dispositive power over those shares. The Form 4 is signed by Max Eisenberg as Chief Operating Officer for the reporting entities.

Positive

  • Full disclosure of multiple sales across reporting entities with footnotes explaining indirect ownership and price ranges
  • Signatures from authorized officer (Max Eisenberg) for all reporting entities, indicating proper execution

Negative

  • Large aggregate insider sales of 188,094 shares over three trading days, which may be viewed as material liquidity from major holders
  • Sales executed by affiliated funds across several entities, which could reduce the stake held indirectly by the Versant-related vehicles

Insights

TL;DR: Significant insider sales by major venture investors totaling 188,094 shares across three days; watch ownership changes.

The Form 4 documents systematic dispositions by multiple Versant affiliated investment vehicles on August 22, 25 and 26, 2025. The aggregate number of shares reported sold is 188,094, at weighted-average prices within disclosed ranges from about $38.50 to $40.8819. The filings reflect both direct and indirect beneficial ownership movements and leave post-transaction beneficial ownership amounts in the record for each line item. For investors this is a clear disclosure of liquidity activity from large pre-existing holders rather than option exercises or derivative issuances. The filing does not disclose any new derivative transactions or changes to control arrangements.

TL;DR: Multiple affiliated entities reported coordinated sales; governance structure and disclaimers are documented in footnotes.

The submission shows coordinated sales by related limited partnerships and their GP and GP-GP entities, with footnotes explaining indirect holdings and disclaimers of beneficial ownership except for pecuniary interests. Signatures by the same officer (Max Eisenberg) for each entity are present, and the footnotes provide the customary undertaking to supply per-price breakdowns on request. This filing properly documents the chain of ownership and voting/investment power among fund, GP and GP-GP entities, which preserves disclosure quality for governance review. There is no indication in this Form 4 of new governance actions or control changes.

Insider Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold 188,094 shs ($7.42M)
Type Security Shares Price Value
Sale Common Stock 43,978 $38.9744 $1.71M
Sale Common Stock 21,661 $38.9744 $844K
Sale Common Stock 3,465 $39.5022 $137K
Sale Common Stock 1,707 $39.5022 $67K
Sale Common Stock 50,270 $39.5255 $1.99M
Sale Common Stock 24,760 $39.5255 $979K
Sale Common Stock 2,149 $39.9212 $86K
Sale Common Stock 1,058 $39.9212 $42K
Sale Common Stock 20,493 $40.0297 $820K
Sale Common Stock 10,076 $40.0297 $403K
Sale Common Stock 5,668 $40.5899 $230K
Sale Common Stock 2,809 $40.5899 $114K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,277,662 shares (Direct); Common Stock — 902,514 shares (Indirect, See Footnote)
Footnotes (1)
  1. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.5085 to $40.4616, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $40.50 to $40.8819, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.815 to $39.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.81 to $40.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.50 to $39.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.49 to $39.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Versant Venture Capital VI, L.P.
(Last) (First) (Middle)
ONE SANSOME STREET, SUITE 1650
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/22/2025 S 20,493 D $40.0297(1) 1,379,727 D(2)
Common Stock 08/22/2025 S 10,076 D $40.0297(1) 952,802 I See Footnote(3)
Common Stock 08/22/2025 S 5,668 D $40.5899(4) 1,374,059 D(2)
Common Stock 08/22/2025 S 2,809 D $40.5899(4) 949,993 I See Footnote(2)
Common Stock 08/25/2025 S 50,270 D $39.5255(5) 1,323,789 D(2)
Common Stock 08/25/2025 S 24,760 D $39.5255(5) 925,233 I See Footnote(2)
Common Stock 08/25/2025 S 2,149 D $39.9212(6) 1,321,640 D(2)
Common Stock 08/25/2025 S 1,058 D $39.9212(6) 924,175 I See Footnote(2)
Common Stock 08/26/2025 S 43,978 D $38.9744(7) 1,277,662 D(2)
Common Stock 08/26/2025 S 21,661 D $38.9744(7) 902,514 I See Footnote(2)
Common Stock 08/26/2025 S 3,465 D $39.5022(8) 1,274,197 D(2)
Common Stock 08/26/2025 S 1,707 D $39.5022(8) 900,807 I See Footnote(2)
Common Stock 842,162 I See Footnote(9)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Versant Venture Capital VI, L.P.
(Last) (First) (Middle)
ONE SANSOME STREET, SUITE 1650
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Versant Ventures VI GP, L.P.
(Last) (First) (Middle)
ONE SANSOME STREET, SUITE 1650
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Versant Ventures VI GP-GP, LLC
(Last) (First) (Middle)
ONE SANSOME STREET, SUITE 1650
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Versant Vantage II, L.P.
(Last) (First) (Middle)
ONE SANSOME STREET, SUITE 1650
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Versant Vantage II GP, L.P.
(Last) (First) (Middle)
ONE SANSOME STREET, SUITE 1650
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Versant Vantage II GP-GP, LLC
(Last) (First) (Middle)
ONE SANSOME STREET, SUITE 1650
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Versant Venture Capital VII, L.P.
(Last) (First) (Middle)
ONE SANSOME STREET, SUITE 1650
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Versant Ventures VII GP, L.P.
(Last) (First) (Middle)
ONE SANSOME STREET, SUITE 1650
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Versant Ventures VII GP-GP, LLC
(Last) (First) (Middle)
ONE SANSOME STREET, SUITE 1650
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.5085 to $40.4616, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
2. These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
3. These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $40.50 to $40.8819, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
5. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.815 to $39.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
6. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.81 to $40.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
7. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.50 to $39.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.
8. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.49 to $39.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.
9. These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
Versant Vantage II, LP By: Versant Vantage II GP, L.P. Its: General Partner By: Versant Vantage II GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer 08/26/2025
Versant Vantage II GP, L.P., By: Versant Vantage II GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer 08/26/2025
Versant Vantage II GP-GP, LLC, By: /s/ Max Eisenberg Its: Chief Operating Officer 08/26/2025
Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner By: Versant Ventures VI GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer 08/26/2025
Versant Ventures VI GP, L.P., By: Versant Ventures VI GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer 08/26/2025
Versant Ventures VI GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer 08/26/2025
Versant Venture Capital VII, L.P. By: Versant Ventures VII GP, L.P. Its: General Partner By: Versant Ventures VII GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer 08/26/2025
Versant Ventures VII GP, L.P., By: Versant Ventures VII GP-GP, LLC Its: General Partner By: /s/ Max Eisenberg Its: Chief Operating Officer 08/26/2025
Versant Ventures VII GP-GP, LLC By: /s/ Max Eisenberg Its: Chief Operating Officer 08/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What transactions does the LENZ Form 4 report?

The Form 4 reports multiple sales of common stock by Versant-related entities on August 22, 2025, August 25, 2025 and August 26, 2025.

How many LENZ shares were sold in total in this filing?

The filing lists aggregate sales of 188,094 shares across the reported transactions.

What price ranges were reported for the sales of LENZ shares?

Weighted-average prices are reported with transaction price ranges disclosed in footnotes, spanning approximately $38.50 to $40.8819 per share.

Which entities reported the transactions for LENZ (ticker LENZ)?

Reporting entities include Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P., Versant Vantage II, L.P. and related GP and GP-GP entities, as shown on the Form 4.

Do the filings indicate direct or indirect ownership after the sales?

Yes; each line shows whether the post-transaction ownership is Direct (D) or Indirect (I), and footnotes explain which shares are held indirectly by the various Versant funds.

Who signed the Form 4 for the reporting entities?

The Form 4 is signed by Max Eisenberg in the capacity of Chief Operating Officer for the reporting entities on August 26, 2025.